BIO-key International, Inc. (NASDAQ:BKYI) Q2 2022 Earnings Conference Call August 12, 2022 10:00 AM ET Company Participants William Jones - Vice President, Catalyst Global LLC Michael DePasquale - Chief Executive Officer Alex Rocha - Managing Director, EMEA Cecilia Welch - Chief Financial Officer Conference Call Participants Jack Vander Aarde - Maxim Group LLC Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to BIO-key International Second Quarter Conference Call. During m ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT | --- | --- | |-----------------------------------------------------------------------------------|----------------------------| | For the Transition Period from | to | | Commission file number | 1-13463 | | BIO-KEY INTERNATIONAL, INC. (Exact ...

BIO-key International, Inc. (NASDAQ:BKYI) Q1 2022 Earnings Conference Call May 16, 2022 10:00 AM ET Company Participants Kimberly Johnson - Vice President, Product Mike DePasquale - Chairman and CEO Ceci Welch - CFO Conference Call Participants Jack Vander Aarde - Maxim Group Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to BIO-key International's First Quarter 2022 Conference Call. During management's prepared remarks all participants will be a listen-only mode. Afterw ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BKYI Nasdaq Capital Market ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___ TO ___ COMMISSION FIL ...

BIO-key International, Inc. (NASDAQ:BKYI) Q4 2021 Earnings Conference Call March 29, 2022 10:00 AM ET Company Participants Kimberly Biddings - Vice President of Product Mike DePasquale - Chairman and Chief Executive Officer Alex Rocha - President, BIO-key EMEA Ceci Welch - Chief Financial Officer Conference Call Participants Jack Vander Aarde - Maxim Group Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are des ...

| --- | --- | |----------------------------------------------------------------------------------|-------| | | | | Identity & Access Management and IdentityBound Biometric Cybersecurity Solutions | | | March 2022 | | | www.BIO-key.com | | | | | | | | 2 Safe Harbor All statements contained herein other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT For the Transition Period from to Commission file number 1-13463 BIO-KEY INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 41-1741861 (State or Other Jurisdiction of Incorporation of Organizati ...

BIO-key International, Inc. (NASDAQ:BKYI) Q2 2021 Earnings Conference Call August 17, 2021 10:00 AM ET Company Participants Kimberly Johnson - VP, Product Marketing Michael DePasquale - Chairman and CEO Fred Corsentino - Chief Revenue Officer Cecilia Welch - Chief Financial Officer Conference Call Participants Jack Vander Aarde - Maxim Group Operator Good morning, ladies and gentlemen. And thank you for standing by and welcome to BIO-key International’s Second Quarter 2021 Conference Call. During management ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT For the Transition Period from to Commission file number 1-13463 BIO-KEY INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 41-1741861 (State or Other Jurisdiction of Incorporation of Organization) (IRS Emplo ...

U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT For the Transition Period from to Commission file number 1-13463 BIO-KEY INTERNATIONAL, INC. (Exact Name of registrant as specified in its charter) DELAWARE 41-1741861 (State or Other Jurisdiction of Incorporation of Organization) (IRS Employe ...